Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform

Stock Information for Tempest Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Tempest Therapeutics Inc.

Tempest Therapeutics Announces Up to $7.5 Million Private Placement
Tempest to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update
Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T
Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026
Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors
Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds
Tempest Reports First Quarter 2026 Financial Results and Provides Business Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.